Tazemetostat hydrobromide

本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断

Tazemetostat Hydrobromide 是一种有效的选择性 EZH2 抑制剂。

Tazemetostat hydrobromide is a potent and selective EZH2 inhibitor. Tazemetostat hydrobromide inhibits the activity of human polycomb repressive complex 2 (PRC2)-containing wild-type EZH2 (Ki: 2.5 nM). Tazemetostat hydrobromide also inhibits EZH1 (IC50: 392 nM).(In Vitro):Tazemetostat hydrobromide inhibits Rat EZH2 (IC50: 4 nM). Tazemetostat hydrobromide inhibits EZH2 with IC50s of 11 and 16 nM in peptide assay and nucleosome assay, respectively. Tazemetostat hydrobromide inhibits multi wild-type and mutant lymphoma cell lines proliferation with IC50s of 0.49 nM-7.6 μM .(In Vivo):Tazemetostat (250 or 500 mg/kg twice daily for 21-28 days) practically eliminates the fast-growing G401 tumors .

——

——

EPZ-6438 hydrobromide | E-7438 hydrobromide

Chromatin/Epigenetic

Histone Demethylase

microtubule

——

——

1467052-75-0

653.662

C34H45BrN4O4

>98% (HPLC)

——

Br.CCN(C1CCOCC1)c1cc(cc(C(=O)NCc2c(C)cc(C)[nH]c2=O)c1C)-c1ccc(CN2CCOCC2)cc1

——

(-20℃)

With Ice Pack

≥ 2 years